e-learning
resources
Virtual 2021
06.09.2021
Exercise tolerance, supportive care and more in non-pulmonary fibrosis interstitial lung diseases
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Late Breaking Abstract - Prognostic value of serum biomarkers in patients with idiopathic pulmonary fibrosis and correlation with disease progression.
K. Domvri (Thessaloniki, Greece), A. Apostolopoulos (Thessaloniki, Greece), I. Organtzis (Thessaloniki, Greece), E. Fouka (Thessaloniki, Greece), L. Bina (Thessaloniki, Greece), T. Kontakiotis (Thessaloniki, Greece), D. Papakosta (Thessaloniki, Greece)
Source:
Virtual Congress 2021 – Exercise tolerance, supportive care and more in non-pulmonary fibrosis interstitial lung diseases
Session:
Exercise tolerance, supportive care and more in non-pulmonary fibrosis interstitial lung diseases
Session type:
E-poster
Number:
2348
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
K. Domvri (Thessaloniki, Greece), A. Apostolopoulos (Thessaloniki, Greece), I. Organtzis (Thessaloniki, Greece), E. Fouka (Thessaloniki, Greece), L. Bina (Thessaloniki, Greece), T. Kontakiotis (Thessaloniki, Greece), D. Papakosta (Thessaloniki, Greece). Late Breaking Abstract - Prognostic value of serum biomarkers in patients with idiopathic pulmonary fibrosis and correlation with disease progression.. 2348
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: Diagnostic tools for Obstructive Sleep Apnoea in adults and children
Expert interview: Physiological classification of lung function impairment
Occupational exposures to respiratory diseases: A case-based discussion
Related content which might interest you:
MMP-7 is a predictive biomarker of disease progression in patients with idiopathic pulmonary fibrosis
Source: ERJ Open Res, 3 (1) 00074-2016; 10.1183/23120541.00074-2016
Year: 2017
Late Breaking Abstract - Systemic ferritin is an early disease biomarker for silicosis patients
Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases
Year: 2021
Late Breaking Abstract - Elevated growth differentiation factor 15 in serum correlated with acute exacerbation of idiopathic pulmonary fibrosis
Source: International Congress 2019 – Idiopathic pulmonary fibrosis and surroundings
Year: 2019
Serum exosomes from IPF patients display a fibrotic miRNA profile that correlates to clinical measures of disease severity
Source: International Congress 2015 – Interstitial lung diseases II
Year: 2015
Late Breaking Abstract - Correlation of CT severity score and Inflammatory markers to predict the disease severity in COVID 19 patients
Source: Virtual Congress 2021 – COVID – 19: treatments and predictive factors
Year: 2021
Late Breaking Abstract - Survival and course of lung function in patients with idiopathic pulmonary fibrosis with or without antifibrotic treatment: long-term results of the INSIGHTS-IPF registry
Source: International Congress 2019 – Idiopathic pulmonary fibrosis and surroundings
Year: 2019
Prognostic evaluation in Chinese patients with idiopathic pulmonary fibrosis
Source: Annual Congress 2008 - Management of idiopathic pulmonary fibrosis: what can we learn from the pathophysiology?
Year: 2008
Correlation between physical activity and prognostic markers in patients with idiopathic pulmonary fibrosis
Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis
Year: 2020
Serum KL-6 as a multidimensional biomarker in patients with idiopathic pulmonary fibrosis
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
Clinical significance of autoantibody screening in patients with idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Diffuse pulmonary fibrosis
Year: 2013
Discovery and validation of peripheral blood gene expression profiles predictive of poor outcome and disease progression in idiopathic pulmonary fibrosis
Source: International Congress 2014 – Pathogenetic mechanisms in pulmonary fibrosis
Year: 2014
Prognostic evaluation in idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2011 - What is new in the approach to pulmonary fibrosis?
Year: 2011
Late Breaking Abstract - Association of lung clearance index with survival in patients with cystic fibrosis
Source: International Congress 2019 – Advances in care and monitoring of cystic fibrosis
Year: 2019
Clinical course of idiopathic pulmonary fibrosis (IPF): Prediction and outcome
Source: Annual Congress 2011 - What is new in the approach to pulmonary fibrosis?
Year: 2011
Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis
Source: Annual Congress 2004 - Fibrosing lung diseases
Year: 2004
Late Breaking Abstract - Increased serum levels of YKL-40 in male smoking chronic obstructive pulmonary disease patients associated with altered miRNA levels in alveolar macrophages
Source: Virtual Congress 2020 – New biomarkers for management of obstructive diseases
Year: 2020
Correlation of a progression of fibrotic changes in idiopathic pulmonary fibrosis 1 year after a diagnosis with initial functional and immunologic parameters
Source: Eur Respir J 2004; 24: Suppl. 48, 667s
Year: 2004
IL8 as a marker of severity of disease progression in patients with idiopathic pulmonary fibrosis (IPF)
Source: Eur Respir J 2007; 30: Suppl. 51, 373s
Year: 2007
Incidence and predictive factors of lung cancer in patients with idiopathic pulmonary fibrosis
Source: ERJ Open Res, 4 (1) 00111-2016; 10.1183/23120541.00111-2016
Year: 2018
Functional and prognostic significance of relationship between VC and TLC in patients with idiopathic pulmonary fibrosis (IPF)
Source: Eur Respir J 2005; 26: Suppl. 49, 334s
Year: 2005
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept